Wirkungen der Bronchodilatation mit Salmeterol auf das autonome Nervensystem

Bornemann, Thore

dc.contributor.advisor	Andreas, Stefan Prof. Dr.
dc.contributor.author	Bornemann, Thore
dc.date.accessioned	2015-05-26T07:57:32Z
dc.date.available	2015-06-22T22:50:11Z
dc.date.issued	2015-05-26
dc.identifier.uri	http://hdl.handle.net/11858/00-1735-0000-0022-5FF3-5
dc.identifier.uri	http://dx.doi.org/10.53846/goediss-4730
dc.language.iso	deu	de
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/3.0/
dc.subject.ddc	610	de
dc.title	Wirkungen der Bronchodilatation mit Salmeterol auf das autonome Nervensystem	de
dc.type	doctoralThesis	de
dc.title.translated	Effects of bronchodilatation with salmeterol on the autonomic nervous system	de
dc.contributor.referee	Andreas, Stefan Prof. Dr.
dc.date.examination	2015-06-15
dc.description.abstracteng	Abstract: Neurohumoral activation is present in COPD and might provide a link between pulmonary and systemic effects, especially cardiovascular disease. Because long acting inhaled β-agonists reduce hyperinflation, they could reduce sympathoexcitation by improving the inflation reflex. We aimed to evaluate if inhaled therapy with salmeterol reduces muscle sympathetic nerve activity (MSNA) evaluated by microneurography. Methods: MSNA, heart rate, blood pressure, and respiration were continually measured as placebo and salmeterol (50 μg) were inhaled sequentially. Following 4 weeks of treatment with salmeterol 50 μg twice daily, measurements were repeated without placebo administration. Results: A total of 32 COPD patients were included. Valid MSNA signals were obtained from 18 patients. Change in MSNA (bursts/100 heart beats) following acute administration of salmeterol did not differ significantly from the change following placebo (-1.96 ± 9.81 vs. -0.65 ± 9.07; p=0.51) although hyperinflation was significantly reduced. Likewise, no changes in MSNA or catecholamines were observed after 4 weeks. Salmeterol treatment was safe and well tolerated. Conclusions: By using microneurography as a gold standard to evaluate sympathetic activity we found no change in MSNA following salmeterol inhalation. Thus, despite an attenuation of hyperinflation, the long acting β-agonist salmeterol does not appear to reduce nor incite sympathoexcitation.	de
dc.contributor.coReferee	Kazmaier, Stephan PD Dr.
dc.subject.ger	MSNA	de
dc.subject.ger	COPD	de
dc.subject.eng	COPD	de
dc.subject.eng	MSNA	de
dc.subject.eng	Salmeterol	de
dc.subject.eng	Neurohumoral activation	de
dc.subject.eng	cardiovascular	de
dc.subject.eng	pulmonary	de
dc.subject.eng	hyperinflation	de
dc.subject.eng	sympathoexcitation	de
dc.identifier.urn	urn:nbn:de:gbv:7-11858/00-1735-0000-0022-5FF3-5-9
dc.affiliation.institute	Medizinische Fakultät	de
dc.subject.gokfull	Medizin (PPN619874732)	de
dc.subject.gokfull	Pneumologie (PPN619875801)	de
dc.description.embargoed	2015-06-22
dc.identifier.ppn	826068197

Dateien

Name:Dissertation_TBornemann_150518_ohne.pdf

Größe:1.201Mb

Format:PDF

Öffnen

Name:: Dissertation_TBornemann_150518 ...
Größe:: 1.201Mb
Format:: PDF

Öffnen

Das Dokument erscheint in:

Human- und Zahnmedizin [2872]

Zur Kurzanzeige